Uses of the drug Sunmesacol

1.1 Indications Sunmesacol is indicated for use in the following cases:
Indication for the treatment of mild to moderate acute ulcerative colitis and in the maintenance of remission of ulcerative colitis. Indicated for the treatment of ileitis in active and maintenance Crohn's disease. 1.2 How to use - Dosage How to use:
Sunmesacol is used orally.
Dosage:
Acute treatment: 6 tablets/day, divided dose, concomitant treatment with corticosteroids when clinically indicated.
Maintenance treatment: Recommended dose 3-6 tablets/day, divided dose or as directed by the doctor.
Special Cases:
Children: Safety and efficacy have not been fully established in this age group.
Elderly: Since elderly patients are more likely to have impaired renal function, this drug should be prescribed with caution. It is recommended that all patients be assessed for renal function prior to initiating mesalamine and during treatment. Care should be taken to strictly control the blood cell count during treatment.
Note: The above dosage is for reference only. The specific dose depends on the condition and the progression of the disease. To get the right dose, you need to consult your doctor or healthcare professional.
1.3 Missing dose, overdose and handling There is no clinical experience with mesalamine overdose. Sunmesacol is an aminosalicylate and symptoms of salicylate toxicity may also occur: Dizziness, tinnitus, headache, confusion, drowsiness, sweating, hyperventilation, vomiting and diarrhea. Severe salicylate toxicity can lead to electrolyte and blood pH imbalances, increased temperature, and dehydration.
Because mesalamine is an aminosalicylate, standard treatment for salicylate toxicity may be beneficial in the event of an acute overdose. This treatment may include preventing the drug from being absorbed from the gastrointestinal tract by inducing vomiting and, if necessary, gastric lavage. Fluid and electrolyte imbalances can be corrected with appropriate intravenous fluids. Adequate renal function should be monitored.
Missed dose:
Add dose as soon as you remember. However, if the interval between the next dose is too short, skip the missed dose and resume the dosing schedule. Do not take a double dose to make up for a missed dose.

When using Sunmesacol, you may experience unwanted effects (ADRs). Common, ADR >1/100:
Gastrointestinal: Diarrhea, dyspepsia, nausea, abdominal pain, hematuria (bloody diarrhea), rectal irritation, exacerbation of ulcerative colitis symptoms. Other: Headache, acne, rash. Instructions on how to handle ADR: When experiencing side effects of the drug, it is necessary to stop using it and notify the doctor or go to the nearest medical facility for timely treatment.

Before using the drug you need to carefully read the instructions for use and refer to the information below.
Contraindications
Sunmesacol is contraindicated in the following cases:
In patients with known hypersensitivity to mesalamine, any of its components, or salicylates. Sunmesacol is not recommended for people with hypersensitivity to any of the ingredients in the last trimester of pregnancy. Increased tendency to bleeding due to drugs that may lower the pH of small or large bowel prolapse. Precautions for use
Because of the dose-related nephrotoxicity in experimental animals, mesalamine preparations are not recommended for use in patients with renal disease or reduced renal function.
Sunmesacol is an aminosalicylate and symptoms of salicylate toxicity may also occur: dizziness, tinnitus, headache, confusion, drowsiness, sweating, hyperventilation, vomiting and diarrhea.
Severe salicylate toxicity can lead to electrolyte and pH imbalances, increased temperature, and dehydration.
Ability to drive and use machines
Do not drive or engage in hazardous work until it is determined how the drug affects your ability to drive and use machines.
Pregnancy
Mesalamin crosses the placental barrier. Sunmesacol should be used during pregnancy only if clearly needed.
Lactation
Small amounts of mesalamine are distributed in breast milk and amniotic fluid of pregnant women during treatment with mesalamin.
Use caution when using Sunmesacol on women who are breastfeeding.

Possible hazardous interactions are unknown. However, lactulose catabolism by bacteria and related agents to the production of organic acids reduces the pH of the colonic intestinal fluid and thus inhibits the disintegration of Eudragit S. Therefore, concomitant administration of Eudragit S is not recommended. Sunmesacol with other pH dependent slow release preparations.